The Clinical Problem

Atherosclerotic plaque is the build up of fat in the arteries causing a narrowing of the blood vessels.

Current clinical management of heart and artery disease relies heavily on medical imaging to help see the disease and determine its extent.

More than 60% of coronary artery disease (CAD) patients have invasive medical imaging which shows that their arteries are free from disease1 – this is both unnecessary and expensive.

Non-invasive coronary CT scans are now the front-line imaging test for patients with suspected CAD.

As a result, the number of CT scans performed is expected to dramatically increase2 placing a strain on already overloaded and under-resourced clinics.

Over 30% of heart attacks occur in people who have no visible CAD blocking the artery3 which means the current methods used to read the CT scans are not appropriate.

Furthermore, when someone has a heart attack and is treated, 1 in 3 will have another heart attack within 2 years4,5.

Current methods cannot see and treat the entire problem, but instead focus on the late-stage markers of disease.

There is a rapidly growing clinical need for highly-automated and efficient risk assessment methods to make better decisions and improve patient outcomes.

Navier Medical is addressing this urgent need.

Our Solution
1. Hanssen et al. EHJ – Qual Care Clin Outcome 2018;4(2):106-112
2. Dreisbach et al. Heart 2018;104:921-7
3. PROMISE Trial. Circ 2017;135(24):2320-32
4. Kwok et al. JACC:Cardiovasc Interv 2019;12:734-8
5. LRP Study. Lancet 2019;394:1629-37